Literature DB >> 17468941

Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment.

Jason C Cole1, Peggy Lin, Marcia F T Rupnow.   

Abstract

OBJECTIVE: Health-related quality of life (HRQoL) is an important outcome measure of migraine treatments. Although a number of migraine-specific HRQoL questionnaires exist, their measurement characteristics have only been examined for patients undergoing acute treatment of migraine. The goal of the current study was to evaluate measurement properties of the widely used Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) within a group of patients undergoing prophylactic migraine treatment.
METHODS: Various measurement properties of the MSQ were examined in a sample of 916 migraineurs undergoing prophylactic treatment who had scores at baseline and follow-up, as well as baseline SF-36. First, we used confirmatory factor analysis (CFA) and differential item functioning (DIF) to assure the accuracy and stability across groups of the MSQ scoring for all three subscales (Role Restrictive, Role Preventive, and Emotional Functioning). Next, item- and scale-level properties were examined, such as item-total correlations, internal consistency, and convergent and discriminant validity.
RESULTS: Initial findings revealed that item 12 (measuring frustration on the Emotional Functioning subscale) performed poorly. Subsequent to its removal, the 13-item MSQ displayed excellent measurement properties, including stable latent structure at baseline and endpoint, no gender or age biases on items, appropriate item-level and scale-level reliabilities, and markedly higher convergent validity compared to discriminant validity.
CONCLUSION: The 13-item MSQ appears to be an appropriate measure of migraine-specific HRQoL for patients undergoing migraine prophylaxis. Moreover, given the stability of the latent structure over time, the interpretation of scores is likely to remain quite consistent throughout a clinical trial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468941     DOI: 10.1007/s11136-007-9217-1

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  14 in total

1.  Development and validation of the Migraine-Specific Quality of Life Questionnaire.

Authors:  P Jhingran; J T Osterhaus; D W Miller; J T Lee; L Kirchdoerfer
Journal:  Headache       Date:  1998-04       Impact factor: 5.887

2.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

3.  Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients.

Authors:  Jason C Cole; Dinesh Khanna; Philip J Clements; James R Seibold; Donald P Tashkin; Harold E Paulus; Michael R Irwin; Sarosh J Motivala; Daniel E Furst
Journal:  Qual Life Res       Date:  2006-07-07       Impact factor: 4.147

Review 4.  Pharmacologic management of acute attacks of migraine and prevention of migraine headache.

Authors:  Vincenza Snow; Kevin Weiss; Eric M Wall; Christel Mottur-Pilson
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

5.  Development and validation of a Rasch-derived CES-D short form.

Authors:  Jason C Cole; Adele S Rabin; Tom L Smith; Alan S Kaufman
Journal:  Psychol Assess       Date:  2004-12

6.  Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1).

Authors:  B C Martin; D S Pathak; M I Sharfman; J U Adelman; F Taylor; W J Kwong; P Jhingran
Journal:  Headache       Date:  2000-03       Impact factor: 5.887

7.  The feasibility of applying item response theory to measures of migraine impact: a re-analysis of three clinical studies.

Authors:  Jakob B Bjorner; Mark Kosinski; John E Ware
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

8.  Using item response theory to calibrate the Headache Impact Test (HIT) to the metric of traditional headache scales.

Authors:  Jakob B Bjorner; Mark Kosinski; John E Ware
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

9.  Calibration of an item pool for assessing the burden of headaches: an application of item response theory to the headache impact test (HIT).

Authors:  Jakob B Bjorner; Mark Kosinski; John E Ware
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

10.  Topiramate for migraine prevention: a randomized controlled trial.

Authors:  Jan Lewis Brandes; Joel R Saper; Merle Diamond; James R Couch; Donald W Lewis; Jennifer Schmitt; Walter Neto; Stefan Schwabe; David Jacobs
Journal:  JAMA       Date:  2004-02-25       Impact factor: 56.272

View more
  33 in total

1.  Acupuncture for migraine prophylaxis: a randomized controlled trial.

Authors:  Ying Li; Hui Zheng; Claudia M Witt; Stephanie Roll; Shu-guang Yu; Jie Yan; Guo-jie Sun; Ling Zhao; Wen-jing Huang; Xiao-rong Chang; Hong-xing Zhang; De-jun Wang; Lei Lan; Ran Zou; Fan-rong Liang
Journal:  CMAJ       Date:  2012-01-09       Impact factor: 8.262

2.  Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.

Authors:  Junhua Yu; Kenneth J Smith; Diana I Brixner
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

3.  Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.

Authors:  Virginia L Stauffer; David W Dodick; Qi Zhang; Jeffrey N Carter; Jessica Ailani; Robert R Conley
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

Review 4.  Assessment of Quality of Life in Migraine.

Authors:  Özlem Taşkapilioğlu; Necdet Karli
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

5.  Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.

Authors:  Vladimir Skljarevski; Tina M Oakes; Qi Zhang; Margaret B Ferguson; James Martinez; Angelo Camporeale; Kirk W Johnson; Qiuling Shan; Jeffrey Carter; Aaron Schacht; Peter J Goadsby; David W Dodick
Journal:  JAMA Neurol       Date:  2018-02-01       Impact factor: 18.302

Review 6.  When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis?

Authors:  Domenico D'Amico; Massimo Leone; Licia Grazzi; Gennaro Bussone
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

7.  The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients.

Authors:  Regina Rendas-Baum; Lisa M Bloudek; Gregory A Maglinte; Sepideh F Varon
Journal:  Qual Life Res       Date:  2012-07-15       Impact factor: 4.147

8.  Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus.

Authors:  Andria Tziakouri; Haritini Tsangari; Costas Michaelides
Journal:  Front Neurol       Date:  2021-07-29       Impact factor: 4.003

9.  Health economic evaluation of acupuncture along meridians for treating migraine in China: results from a randomized controlled trial.

Authors:  Zhu-qing Deng; Hui Zheng; Ling Zhao; Si-yuan Zhou; Ying Li; Fan-rong Liang
Journal:  BMC Complement Altern Med       Date:  2012-06-14       Impact factor: 3.659

10.  Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.

Authors:  Jakub Jedynak; Eric Eross; Astrid Gendolla; Mallikarjuna Rettiganti; Virginia L Stauffer
Journal:  J Headache Pain       Date:  2021-05-28       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.